Genmab, BioNTech Announced Data At ASCO, Showing Investigational Acasunlimab In Combination With Pembrolizumab Resulted In 12-month Overall Survival Rate of 69% In Patients With Previously Treated Metastatic Non-small Cell Lung Cancer
Portfolio Pulse from Charles Gross
Genmab A/S and BioNTech SE announced promising Phase 2 trial data for their investigational bispecific antibody acasunlimab in combination with pembrolizumab, showing a 12-month overall survival rate of 69% in patients with previously treated metastatic non-small cell lung cancer.
June 02, 2024 | 3:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioNTech SE announced positive Phase 2 trial results for acasunlimab in combination with pembrolizumab, showing a 12-month overall survival rate of 69% in mNSCLC patients.
The positive trial results are likely to enhance BioNTech's reputation in oncology, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Genmab A/S announced positive Phase 2 trial results for acasunlimab in combination with pembrolizumab, showing a 12-month overall survival rate of 69% in mNSCLC patients.
The positive trial results are likely to boost investor confidence in Genmab's pipeline, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100